RT Journal Article
T1 Statins in Non-alcoholic Steatohepatitis
A1 Torres-Peña, Jose D.
A1 Martín-Piedra, Laura
A1 Fuentes-Jiménez, Francisco
K1 Statins
K1 NASH
K1 Cardiovascular disease
K1 Liver
K1 Aminotransferase
K1 Hepatocellular carcinoma
K1 Metabolic syndrome
K1 Cirrhosis
K1 Dyslipidemia
K1 Obesity
K1 Anti-inflammatory
K1 Diabetes
K1 Inhibidores de hidroximetilglutaril-CoA reductasas
K1 Enfermedad del hígado graso no alcohólico
K1 Enfermedades cardiovasculares
K1 Hígado
K1 Transaminasas
K1 Carcinoma hepatocelular
K1 Síndrome metabólico
K1 Cirrosis
K1 Fibrosis
K1 Cirrosis hepática
K1 Dislipidemias
K1 Obesidad
K1 Antiinflamatorios
AB Non-alcoholic fatty liver disease (NAFLD) is the primary cause of chronic liver disease. The range is extensive, including hepatocellular carcinoma, cirrhosis, fibrosis, fatty liver, and non-alcoholic steatohepatitis (NASH). NASH is a condition related to obesity, overweight, metabolic syndrome, diabetes, and dyslipidemia. It is a dynamic condition that can regress to isolated steatosis or progress to fibrosis and cirrhosis. Statins exert anti-inflammatory, proapoptotic, and antifibrotic effects. It has been proposed that these drugs could have a relevant role in NASH. In this review, we provide an overview of current evidence, from mechanisms of statins involved in the modulation of NASH to human trials about the use of statins to treat or attenuate NASH.
PB Frontiers
YR 2021
FD 2021-11-24
LK http://hdl.handle.net/10668/4342
UL http://hdl.handle.net/10668/4342
LA en
NO Torres-Peña JD, Martín-Piedra L, Fuentes-Jiménez F. Statins in Non-alcoholic Steatohepatitis. Front Cardiovasc Med. 2021 Nov 24;8:777131
DS RISalud
RD Apr 7, 2025